BioCentury
ARTICLE | Finance

mAbs for the masses

Harbour: Small A round enough to compete with transgenic mouse platform

August 5, 2013 7:00 AM UTC

Even though Harbour Antibodies B.V. is one of at least three biotechs seeking to broadly out-license their transgenic mouse platforms, Atlas Venture was attracted to the deal because the small investment gives the VC a stake in a commercially ready platform.

Atlas was the sole investor in last week's €2.5 million ($3.3 million) series A round...